PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
R&D change of 41.18% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
22.12%
G&A change of 22.12% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.03%
Operating expenses change of 35.03% versus flat Biotechnology costs. Walter Schloss would verify control.
35.03%
Total costs change of 35.03% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
14.84%
D&A growth exceeding 1.5x Biotechnology median of 0.42%. Jim Chanos would check for overinvestment.
-35.35%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-15.72%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-37.55%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.55%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-34.88%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-34.88%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
2.03%
Share count reduction below 50% of Biotechnology median of 0.28%. Jim Chanos would check for issues.
2.03%
Diluted share reduction below 50% of Biotechnology median of 0.25%. Jim Chanos would check for issues.